QuantuMDx And Scienion AG Partner To Commercialise Novel Nanowire Biosensor

Newcastle-Upon-Tyne, England and Berlin, Germany, June 9, 2015: British medical device developer QuantuMDx (QMDx) and German life sciences company SCIENION have partnered to take QMDx’s highly multiplexed nanowire array to market. This biosensor is a component of QMDx’s flagship product Q-POC™, a handheld molecular diagnostic device that will provide results in 15 minutes for a few pounds at the patient’s side.

QMDx utilises SCIENION’s proprietary ultra-low volume liquid handling technologies to transfer biological material onto QMDx’s novel biosensor. Each nanowire in the array is printed with molecular probes; with hundreds of nanowires in each silicon biosensor chip, the multiplexing potential is massive.

The companies’ longstanding relationship was cemented with QMDx’s purchase of SCIENION’s sciFLEXARRAYER SX, and will continue to grow as the companies embark on a number of development projects to take the biosensor characterisation from R&D to mass manufacture.

The instrument is the newest fixture in QMDx’s chemistry facility at the University of Newcastle upon Tyne’s Chemical Nanoscience Laboratories.

QMDx’s Head of Chemistry Dr Joseph Hedley said “The flexibility and ease of use of the sciFLEXARRAYER SX has enabled a rapid ramp up in QMDx’s R&D activities, and we look forward to working with them on a number of exciting projects that will help bring this device to market.”

"We're thrilled to be working with QuantuMDx" said Holger Eickhoff, CEO of SCIENION. "I look forward to our collaboration and believe that our work together will produce some fantastic developments that help foster some disruptive diagnostic innovations."

Help employers find you! Check out all the jobs and post your resume.

Back to news